US Bancorp DE Buys 271 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

US Bancorp DE grew its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 4.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,549 shares of the biotechnology company’s stock after buying an additional 271 shares during the period. US Bancorp DE’s holdings in Sarepta Therapeutics were worth $818,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Oppenheimer Asset Management Inc. boosted its stake in Sarepta Therapeutics by 32.0% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 3,604 shares of the biotechnology company’s stock worth $467,000 after purchasing an additional 874 shares in the last quarter. Swiss National Bank boosted its stake in Sarepta Therapeutics by 6.3% in the 1st quarter. Swiss National Bank now owns 166,183 shares of the biotechnology company’s stock worth $21,514,000 after purchasing an additional 9,900 shares in the last quarter. Sei Investments Co. boosted its stake in Sarepta Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 61,451 shares of the biotechnology company’s stock worth $7,956,000 after purchasing an additional 5,332 shares in the last quarter. ProShare Advisors LLC boosted its stake in Sarepta Therapeutics by 10.1% in the 1st quarter. ProShare Advisors LLC now owns 6,578 shares of the biotechnology company’s stock worth $852,000 after purchasing an additional 601 shares in the last quarter. Finally, Orion Portfolio Solutions LLC boosted its stake in Sarepta Therapeutics by 44.8% in the 1st quarter. Orion Portfolio Solutions LLC now owns 10,096 shares of the biotechnology company’s stock worth $1,307,000 after purchasing an additional 3,123 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Up 1.0 %

Shares of NASDAQ SRPT opened at $121.61 on Friday. The stock’s 50 day moving average price is $125.92 and its two-hundred day moving average price is $132.91. Sarepta Therapeutics, Inc. has a 52-week low of $75.85 and a 52-week high of $173.25. The stock has a market capitalization of $11.60 billion, a P/E ratio of 97.29 and a beta of 0.81. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 11.72% and a net margin of 7.43%. The business had revenue of $362.90 million for the quarter, compared to analysts’ expectations of $394.38 million. During the same period in the prior year, the firm earned ($0.27) EPS. The business’s quarterly revenue was up 38.9% on a year-over-year basis. On average, analysts anticipate that Sarepta Therapeutics, Inc. will post 1.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SRPT. Guggenheim upped their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday. William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Raymond James reiterated an “outperform” rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $152.00 to $167.00 in a research report on Thursday. Finally, UBS Group boosted their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a hold rating, twenty have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics has an average rating of “Buy” and an average price target of $181.33.

Insider Activity

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Michael Andrew Chambers purchased 37,038 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the acquisition, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.